Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2009 | Original Article

Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women

Authors: Yaprak Engin-Üstün, Yusuf Üstün, Ilgın Türkçüoğlu, M. Mutlu Meydanlı, Ayşe Kafkaslı, Gülay Yetkin

Published in: Archives of Gynecology and Obstetrics | Issue 3/2009

Abstract

Objective

To evaluate the effects of tibolone on the serum C-reactive protein (CRP) in hypertensive postmenopausal women.

Methods

We enrolled 45 postmenopausal patients with hypertension and 17 normotensive postmenopausal women. Inclusion criteria were surgical menopause, the presence of vasomotor symptoms, and normal mammogram within 1 year, the absence of documented coronary artery disease, and normal electrocardiography. Forty hypertensive women and 17 normotensive women completed the 3-month period. Twenty-one hypertensive women received tibolone, whereas 19 served as control. At baseline and at 3 months, blood lipids and CRP were evaluated.

Results

Changes in lipid profile and CRP in the hypertensive and normotensive control groups during 3 months were not statistically significant. Total cholesterol levels decreased significantly after 3 months of tibolone treatment. A significant increase in CRP values was observed in the tibolone group (p = 0.001).

Conclusion

This trial demonstrated that tibolone treatment induced a significant increase in CRP and a significant decrease in total cholesterol in postmenopausal hypertensive women.

Barnes JF, Farish E, Rankin M, Hart DM (2002) A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 160:185–193. doi:10.1016/S0021-9150(01)00560-3 PubMedCrossRef

Barnes JF, Farish E, Rankin M, Hart DM (2005) Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause 12:92–98. doi:10.1097/00042192-200512010-00016 PubMedCrossRef

Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C (1997) Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82:1752–1756. doi:10.1210/jc.82.6.1752 PubMedCrossRef

Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J et al (1999) Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause 6:92–97. doi:10.1097/00042192-199906020-00004 PubMedCrossRef

Davison S, Davis SR (2003) New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 88:2470–2478. doi:10.1210/jc.2002-021929 PubMedCrossRef

Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM (2008) Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 6:928–934. doi:10.1111/j.1538-7836.2008.02970.x PubMedCrossRef

Garnero P, Jamin C, Benhamou CL, Pelissier C, Roux C (2002) Effects of tibolone and combined 17β-estradiol and norethisterone acetate on serum C-reactive protein in healthy postmenopausal women: a randomized trial. Hum Reprod 17:2748–2753. doi:10.1093/humrep/17.10.2748 PubMedCrossRef

Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH (1997) Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomized study. Br J Obstet Gynaecol 104:708–717PubMed

Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289:2560–2572. doi:10.1001/jama.289.19.2560 CrossRef

10.

Kenemans P, Speroff L, International Tibolone Consensus Group (2005) Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 51:21–28. doi:10.1016/j.maturitas.2005.02.011 PubMedCrossRef

11.

Kiran H, Kiran G (2006) Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women. Arch Gynecol Obstet 274:9–12. doi:10.1007/s00404-005-0111-1 PubMedCrossRef

12.

Lloyd G, McGing E, Cooper A, Patel N, Lumb PJ, Wierzbicki AS et al (2000) A randomized placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 14:99–104. doi:10.1038/sj.jhh.1000938 PubMedCrossRef

13.

Mahmud A, Feely J (2002) Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 15:321–325. doi:10.1016/S0895-7061(01)02313-5 PubMedCrossRef

14.

Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S (2007) Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy—inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung 57:698–704PubMed

15.

Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Anzai T, Meguro T et al (2007) Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail 13:365–371. doi:10.1016/j.cardfail.2007.02.004 PubMedCrossRef

16.

Palmas W, Ma S, Psaty B, Goff DC Jr, Darwin C, Barr RG (2007) Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens 20:233–241. doi:10.1016/j.amjhyper.2006.08.006 PubMedCrossRef

17.

Pepys MB, Berger A (2001) The renaissance of C reactive protein. BMJ 322:4–5. doi:10.1136/bmj.322.7277.4 PubMedCrossRef

18.

Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP (2002) A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 77:945–951. doi:10.1016/S0015-0282(02)03078-9 PubMedCrossRef

19.

Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843. doi:10.1056/NEJM200003233421202 PubMedCrossRef

20.

Rifai N, Ridker PM (2001) Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 47:28–30PubMed

21.

Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D (2005) Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 27:578–587. doi:10.1016/j.clinthera.2005.05.006 PubMedCrossRef

22.

Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M (2003) Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169:155–158. doi:10.1016/S0021-9150(03)00158-8 PubMedCrossRef

23.

Todorova M, Kamenov Z, Christov V, Baleva M (2006) Inflammatory activity and anticardiolipin antibodies during tibolone treatment of healthy postmenopausal women. Methods Find Exp Clin Pharmacol 28:147–149. doi:10.1358/mf.2006.28.3.985168 PubMedCrossRef

24.

Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M et al (1997) Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 17:1121–1127PubMed

25.

Van Baal WM, Kenemans P, Van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD (1999) Increased C-reactive protein levels during short term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 81:925–928PubMed

26.

Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E et al (2005) Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 12:552–558. doi:10.1097/01.gme.0000172267.24949.70 PubMedCrossRef

27.

Yıldırır A, Aybar F, Tokgozoglu L, Yarali H, Kabakci G, Bukulmez O et al (2002) Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 53:54–58. doi:10.1159/000049412 PubMedCrossRef

28.

Zandberg P, Peters JLM, Demacker PN, de Reeder EG, Smit MJ, Meuleman DG (2001) Comparison of the anti-atherosclerotic effect of tibolone with that of estradiol and ethynil estradiol in cholesterol-fed, ovariectomized rabbits. Menopause 8:96–105. doi:10.1097/00042192-200103000-00004 PubMedCrossRef

Title: Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women
Authors: Yaprak Engin-Üstün
Yusuf Üstün
Ilgın Türkçüoğlu
M. Mutlu Meydanlı
Ayşe Kafkaslı
Gülay Yetkin
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 3/2009
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-008-0712-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women

Abstract

Objective

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2009

Esophageal carcinoma during pregnancy: a case report

Bladder injuries during cesarean section in a University Hospital: a 25-year review

The sexual activity during pregnancy among a group of Iranian women

Colon penetration by a copper intrauterine device: a case report with literature review

Migration of levonorgestrel IUS in a patient with complex medical problems: what should be done?

Relationship between Cardiofemoral Index and the plasma concentration of brain natriuretic peptide in anemic fetuses associated with Rh alloimmunization